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Abstract
Manually curated variant knowledgebases and their associated knowledge models are serving an increasingly
important role in distributing and interpreting variants in cancer. These knowledgebases vary in their level of public
accessibility, and the complexity of the models used to capture clinical knowledge. CIViC (Clinical Interpretation of
Variants in Cancer - www.civicdb.org) is a fully open, free-to-use cancer variant interpretation knowledgebase that
incorporates highly detailed curation of evidence obtained from peer-reviewed publications and meeting abstracts,
and currently holds over 6300 Evidence Items for over 2300 variants derived from over 400 genes. CIViC has seen
increased adoption by, and also undertaken collaboration with, a wide range of users and organizations involved in
research. To enhance CIViC’s clinical value, regular submission to the ClinVar database and pursuit of other regulatory
approvals is necessary. For this reason, a formal peer reviewed curation guideline and discussion of the underlying
principles of curation is needed. We present here the CIViC knowledge model, standard operating procedures (SOP) for
variant curation, and detailed examples to support community-driven curation of cancer variants.
Keywords: Cancer, Variant, Curation, Standard operating procedure, Knowledgebase
Introduction
Expansion of pan-cancer sequencing efforts in research
and clinical settings has led to a rapid increase in the
number of variants that require clinical annotation [1–5].
Substantial computational and manual requirements for
variant identification and interpretation have been shown
to hinder the development of optimal treatment protocols
for patients [6, 7]. These issues highlight the need for nor-
malized clinical classification and representation of rele-
vant variants, as well as open distribution of a
standardized cancer variant knowledgebase [8, 9]. Manual
curation is an essential part of establishing such a
knowledgebase. The harmonization of these curation
practices to standard operations procedures (SOPs) would
improve quality control and interoperability, facilitating
regulatory approval of these curation efforts, especially in
the case where these SOPs have been subjected to peer re-
view. SOPs designed to guide a formalized curation effort
should outline the structure of the knowledge model, give
specific guidance for the curation of each of the model’s
elements, and detail how specific guidelines and variant
classification systems such as those provided by the
American College of Medical Genetics (ACMG), the
American Society of Clinical Oncology (ASCO) and the
Association for Molecular Pathology (AMP) [10, 11] are
utilized during curation. We previously reported the re-
lease of the Clinical Interpretation of Variants in Cancer
(CIViC) knowledgebase (www.civicdb.org) [12] with only
informal online documentation to guide curation. Here,
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we provide an SOP which will be enforced by all CIViC
Editors during moderation of all submitted curation, with
the intent to formalize curation into CIViC, and also pro-
vide possible motivation for other resources in the field to
offer curation SOPs for peer review.
The main text outlines the four principal components of
the CIViC knowledgebase (Genes, Variants, Evidence
Items, and Assertions) and their associated features.
Genes, have collections of associated Variants, where each
Variant is supported by at least one literature or confer-
ence abstract-derived piece of Evidence (Evidence Item or
EID). Multiple Evidence Items describing a single Variant
in a specific clincal context can be summarized into a
CIViC Assertion. The supplemental materials provide de-
tailed examples and guidelines for curation (see “Curation
Practices”) of each element, with emphasis on understand-
ing many of the nuances of cancer variant curation. Com-
mon challenges, especially for new CIViC Curators, which
could introduce inconsistencies into the database are ad-
dressed throughout the SOP. Further details on the CIViC
knowledge model, standards and guidelines for curation
and moderation, and details on the CIViC project are
available in the CIViC help documents (docs.civicdb.org).
The CIViC knowledge model and key components
The CIViC knowledge model for clinical variants
The CIViC knowledgebase was built to permit both con-
sumption (i.e., searching, browsing, and downloading) of
existing entries as well as curation of new content. The
knowledgebase has been organized into a four-level hier-
archy: Genes, Variants, Evidence Items, and Assertions
(Fig. 1a). Each level has its own knowledge model. All
data created using these knowledge models are available
through a web interface (www.civicdb.org) and an appli-
cation programming interface (API, http://docs.civicdb.
org/en/latest/api.html).
For content creation, CIViC Curators can add or suggest
revisions to curated content at each level (Fig. 1b). Adding
content involves submitting new Evidence Items or Asser-
tions that subsequently undergo revision and review by
CIViC Editors. Revision of content involves adding or revis-
ing the clinical summary and/or its associated features.
Once changes are made within the CIViC database, the ad-
ditions/revisions become visible directly or on a separate re-
vision page depending on the type of submission. Curation
is listed as a “submitted” (i.e., pending) until it is accepted
by an Editor, who is given power to accept or reject Curator
submissions. Curators may reject (but not accept) their
own submissions/revisions. Editors are required to fill out a
conflict of interest statement (Additional file 1: Figure S1).
Further information on Roles in CIViC (Curator, Editor,
etc) is in Additional file 1: Table S1, and for a list of User
Actions in CIViC see Additional file 1: Table S2.
General curation practices
CIViC Curators should avoid directly copying phrases
from original sources (including abstracts) for summar-
ies, statements, and comments. This practice prevents
plagiarism and copyright infringement for articles with
limited public access. Suggested revisions require a com-
ment, generally providing rationale for the change. This
allows CIViC Editors to better understand the changes
being proposed and facilitates acceptance or further
modification. The Source Record Page (Additional file 1:
Figure S2) gives an overview of evidence and ability to
comment on an evidence source. The Source Suggestion
(Additional file 1: Figure S3) offers a rapid and simple
means to contribute to CIViC. If a Curator finds inaccur-
acies or inconsistencies in the database, they should flag
such entities to assist Editors in rectifying curation issues,
using the flag button at the upper left of CIViC curatable
elements (seen in Additional file 1: Figures S1A, S4, S5, and
other screenshots in the supplement). Other useful curation
features that are found throughout CIViC are described in
Additional file 1: Table S3. A workflow for evidence cur-
ation is given in Additional file 1: Figure S6.
Structure and curation of the gene knowledge model
Structure of the gene knowledge model
The Gene knowledge model consists of a Gene Summary
which discusses the clinical relevance of the gene in can-
cer, providing context for the CIViC Variants associated
with the Gene, and may specifically mention variants
which are prominent in certain cancers. It also contains
other structured elements including Gene Name, Gene
Summary, external link to The Drug Gene Interaction
Database [13–15], useful citations on the overall clinical
relevance of the gene, and link-out details from MyGene.
info [16] (Fig. 2a). For a Gene record to be created, it must
be associated with at least one CIViC Variant.
Curating within the gene knowledge model
The CIViC Gene Name utilizes the HGNC official
symbol as provided by Entrez, primarily those approved
by the HUGO Gene Nomenclature Committee (HGNC).
Curators must enter a valid Entrez Gene Name (e.g.,
TP53) and should verify the correct entry against the
Entrez Gene ID automatically displayed by the CIViC
interface. Alternative Gene Names (Aliases/Synonyms)
are imported from Entrez and are searchable throughout
the database.
A CIViC Gene Summary should be created to provide
a high-level overview of clinical relevance of cancer vari-
ants for the gene. Gene Summaries should focus on em-
phasizing the clinical relevance from a molecular
perspective and should not describe the biological func-
tion of the gene unless necessary to contextualize its
clinical relevance in cancer. Gene Summaries should
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include relevant cancer subtypes, specific treatments for
the gene’s associated variants, pathway interactions,
functional alterations caused by variants in the gene, and
normal/abnormal functions of the gene with associated
roles in oncogenesis (Additional file 1: Figure S4). A
CIViC Gene Summary should generally be limited to
one or two paragraphs and cite relevant reviews to fur-
ther support the gene’s clinical relevance in cancer.
Structure and curation of the variant knowledge model
Structure of the variant knowledge model
A CIViC Variant represents any molecular alteration with
evidence for clinical relevance in cancer. A new Variant is
added to the CIViC database when a new Evidence Item
for that Variant is submitted. The CIViC definition for a
variant is intentionally broad, to encompass not only simple
variation (e.g., SNVs and indels), but also regional variation
(e.g., exon mutation), or other types of variation (e.g., ex-
pression, amplification, gene fusion, etc.) (Additional file 1:
Table S4). Features within the CIViC Variant knowledge
model include: Variant Summary, Variant Type, HGVS no-
menclature, ClinVar [17] IDs, Variant Evidence Score, rep-
resentative Variant Coordinates and Transcript, associated
Assertions, and external data from MyVariant.info [16]
(Fig. 2). Methods for editing Variant information are shown
in Additional file 1: Figure S5 and an exemplary Variant
entry is shown in Additional file 1: Figure S7.
Curating within the variant knowledge model
The Variant Name describes the specific variant being
interpreted for clinical utility. The Variant Name can be
very specific [e.g., VHL R176fs (c.528delG)], or can refer
Fig. 1 Overview of the CIViC knowledge model for the exploration of existing data (i.e., searching and browsing) and content curation. a The CIViC
knowledge model consists of four interconnected levels that contribute to the content within CIViC: Genes (blue), Variants (orange), Evidence (yellow), and
Assertions (green). Each broadly defined CIViC Variant is associated with a single gene but can have many lines of evidence linking it to clinical relevance.
b CIViC curation typically begins with the submission of an Evidence Item. Creation of an Evidence Item will automatically generate Gene and Variant
records in the knowledgebase if they do not already exist. Once submitted, the Evidence Item undergoes evaluation by expert Editors and (if necessary)
revision with ultimate rejection or acceptance. Accepted Evidence Items can be used to build Assertions, which are visualized at the Variant-level. Similar
cycles of curation and moderation are employed for all curatable entities in CIViC (e.g., Variant Summaries, Coordinates, Assertions)
Danos et al. Genome Medicine           (2019) 11:76 Page 3 of 12
to a collection of variants fitting a named category (i.e.,
categorical variants [18]). Examples of categorical CIViC
Variants include KRAS G12/G13, EGFR Exon 20 Inser-
tion, and PIK3CA Mutation (Additional file 1: Figure S8).
Other Variant Names, including star-allele nomenclature
adopted by the pharmacogenetics field (e.g., DPYD*2A;
Additional file 1: Figure S9) [19] are also supported. A list
of common variant types supported by CIViC are
described in Additional file 1: Table S4. When curating
this field, the most specific Variant Name described by the
source (i.e., publication or abstract) should be used (e.g.,
KRAS G12/G13 rather than KRAS Exon 2 Mutation if the
paper describes individual variant calls).
Variant Aliases are alternative names, descriptions, or
identifiers that differ from the primary CIViC Variant
Name. These terms are manually curated and are
Fig. 2 Overview of the Gene and Variant knowledge models and the structure of Variant Groups. The Gene and Variant knowledge models
shown above display their associated features (including the Variant Groups feature of Variants) and their origins. Features that are linked to their
notes with dotted lines are automatically generated, whenever possible. a Gene data (blue box) consists of curated features (Gene Name,
Summary, Sources) and auto-generated links to external entities (MyGene.info and DGIdb). Each Gene can be associated with any number of
Variants (dark orange box) and Variants can be grouped (light orange box) based on any unifying feature type (e.g., fusions, activating mutations).
b Variant Group features are outlined by the light orange box. These features include a Summary with Sources and associated Variants. c Variant
data (dark orange box) includes the Gene Name, Aliases, HGVS Expressions, Variant Evidence Score, Allele Registry ID, Summary Sources, Variant
Types, ClinVar IDs, MyVariant.info, and Coordinates. Variants can be associated with CIViC Assertions (green) and Evidence Items (yellow)
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incorporated into the search fields within the CIViC inter-
face. Curators should include one or more aliases such as
protein changes on alternative transcripts (e.g., D754Y for
ERBB2 D769Y), dbSNP IDs [20], COSMIC IDs [21] or
other identifiers used in the literature to describe the
variant.
The Variant Summary is a user-defined summary of
the clinical relevance of the specific CIViC Variant. The
Variant Summary should be a synthesis of the existing
Evidence Statements for the CIViC Variant. When cur-
ating a Variant Summary, basic information on recur-
rence rates and biological/functional impact of the
variant may be included, but the focus should be on the
clinical impact. For Predisposing Variants, any appropri-
ate American College of Medical Genetics (ACMG) evi-
dence codes (ACMG-AMP 2015 criteria [10]) that are
not specific to a disease (e.g., PM2) should be recorded
with a summary of supporting evidence (Additional file
1: Figure S10). Associated sources (PubMed IDs), includ-
ing valuable review articles that might not be appropri-
ate for the development of Evidence Items, may be used
as references for the Variant Summary.
Variant Type(s) are used to classify variants by Se-
quence Ontology terms [21, 22]. These terms permit ad-
vanced searching for categories of variants in the CIViC
interface and downstream semantic analyses of CIViC
Variants. The most specific term(s) that can be applied
to a given Variant should be utilized. Use of the Se-
quence Ontology browser (http://www.sequenceontol-
ogy.org/browser/obob.cgi) is recommended to identify
appropriate terms. When choosing variant types, selec-
tion of multiple terms is supported in order to capture
both functional and structural effects of the variant
(Additional file 1: Table S5). However, these terms
should not be ancestors or descendents of one another,
and all selected terms should be descendents of the ‘se-
quence_variant’ term whenever possible.
The Variant Evidence Score sums the Evidence
Scores for all Evidence Items associated with the Vari-
ant. Evidence Item Scores are calculated by multiplying
a weighted Evidence Rating (i.e., one point for each star)
by the values assigned to Evidence Level (i.e., A = 10,
B = 5, C = 3, D = 1, E = 0.5). The Variant Evidence Score
is a relative measure of the total amount of curation in
the database for a specific CIViC Variant and does not
take into account conflicting evidence.
Primary and Secondary Coordinates for each CIViC
Variant are manually curated and verified. Each Variant
is assigned representative genomic coordinates
(Chromosome, Start, Stop, Reference base, and Variant
base) for the assigned reference assembly (e.g., GRCh37).
Primary Coordinates are generated for all Variants. Sec-
ondary Coordinates are utilized for structural variants
involving two loci (e.g., fusion variants). Specific
guidelines for choosing representative coordinates and
transcripts are described below.
Choosing representative coordinates Although mul-
tiple genomic changes can often lead to functionally
equivalent alterations (e.g., same amino acid change),
CIViC uses representative coordinates to provide user-
friendly variant context rather than enumerate all pos-
sible alterations that could cause the Variant. When
choosing a representative CIViC Variant, Curators
should use the most common or highly recurrent alter-
ation observed (Additional file 1: Figures S11 and S12).
Genomic coordinates are 1-based with left-shifted
normalization and include a specified reference assembly
(GRCh37 preferred). Based on manually curated repre-
sentative coordinates, an automated linkout to the
ClinGen Allele Registry [23] is created. This link pro-
vides additional information such as unique and refer-
enceable identifiers and mappings to multiple reference
builds and transcripts for every registered variant with
links to additional resources (e.g., gnomAD, ClinVar). If
the required ClinGen Allele does not yet exist, the Cur-
ator should create a ClinGen account and register it.
Choosing a representative transcript Multiple tran-
scripts can often be annotated for a single gene. For this
reason, a specific protein coding alteration, resulting from
a genomic change, should always be expressed relative to
a specific/individual transcript sequence. CIViC represen-
tative transcripts use the Ensembl archived version 75
(GRCh37), and Curators should always include the tran-
script version number (i.e., ENST00000078429.1 instead
of ENST00000078429). There is rarely only one correct
transcript. Representative transcripts must contain the
variant but are otherwise chosen based on priority criteria
such as: wide use in the literature, having the longest open
reading frame or most exons, containing the most com-
mon exons between transcripts, or having the widest gen-
omic coordinates (Additional file 1: Figure S13). These are
consistent with Ensembl’s glossary definition of canonical.
The CIViC Variant knowledge model supports The
Human Genome Variation Society (HGVS) Sequence
Variant Nomenclature (HGVS Expressions) to de-
scribe sequence variation in genomic, RNA, coding
DNA, and protein coordinates [24] as well as curated
ClinVar IDs for each CIViC Variant. ClinVar IDs and
HGVS nomenclature must be entered individually in the
Variant editing interface and may capture ClinVar IDs
and HGVS entries not described by the representative
coordinates. Manual entry is required (e.g., not automat-
ically linked based on representative coordinates) to per-
mit entries for complex or Categorical CIViC Variants
and to support alternate transcripts and reference build
versions (Additional file 1: Figure S8).
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Structure and curation of the evidence knowledge model
Structure of the evidence knowledge model
At the core of the CIViC knowledge model lies the
CIViC Evidence Item (EIDs). EIDs follow a structured
knowledge model with 12 required fields (Gene name,
Variant Name, Source Type, Variant Origin, Disease,
Evidence Statement, Evidence Type, Evidence Level,
Evidence Direction, Clinical Significance, and Evidence
Rating) with additional optional fields (e.g., Associated
Phenotypes). Based on the Evidence Type, additional re-
quired or optional fields become available (e.g., Predict-
ive Evidence Types require a Drug Name (which will be
linked to an NCIT term when available) and Drug Inter-
action Type if multiple drugs are involved). Figure 3
describes each field with associated requirements for
successful curation and Additional file 1: Figures S14
and S15 show the Evidence Item submission form and
display in the Evidence grid.
Curating within the evidence knowledge model
A Gene Name and Variant Name are required for EID
submission. The Gene Name field will auto-fill using
type-ahead search for genes in the Entrez database or
their associated Aliases. The Variant Name will also
auto-fill based on existing CIViC Variants. User-defined
variants are also permitted if the desired Variant record
does not already exist. To prevent redundancy, it is rec-
ommended that the Curator browse existing Variant
Names for the gene of interest and consider possible
variant synonyms before creating a new CIViC Variant.
Each Evidence Item must be associated with a Source
Type and Source ID, which link the EID to the original
publication supporting clinical claims. Currently, CIViC
accepts publications indexed on PubMed or abstracts
published through the American Society of Clinical On-
cology (ASCO). If a PubMed Source Type is selected,
the Curator can then enter the PubMed ID, which can
be verified by comparing the desired source to the ab-
breviated citation that is automatically generated below
the PubMed ID field. If an ASCO Source Type is se-
lected, the ASCO Web ID should be entered into the
source ID field. Additionally, Clinical Trial Registry
Number(s) are automatically linked via the PubMed
database, when available.
Fig. 3 Diagram of the Evidence Item knowledge model. Evidence Items provide a summarized statement about a variant’s implication in clinical
oncology in the context of structured data. The knowledge model consists of features (yellow box) that are user-generated and human-readable
while leveraging outside ontologies and CIViC-defined fields. Features that are linked to their notes with dotted lines are automatically generated,
whenever possible. The Variant Type, Direction, and Clinical Significance features allow Curators to develop complex Evidence Items with
nuanced meaning while maintaining queryable structure
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The Variant Origin categorizes the variant based on
method of acquisition. Options for this field include:
Somatic, Rare Germline, Common Germline, Unknown,
or N/A. The Variant Origin should be entered as som-
atic if the variant is only found in tumor cells (i.e., a
somatic variant is only found in a proper subset of non-
germ cells/tissue), and is not expected to be inherited or
passed to offspring. The Variant Origin is not applicable
(N/A) in some circumstances, particularly in variants
that involve differences in expression, methylation, or
other post-translational modifications (Additional file 1:
Figure S16).
The Disease field utilizes a term that is known to the
Disease Ontology (DO) database [25]. The field will
auto-fill based on existing diseases (in the cancer subset
of DO) and the most specific disease subtype available
should be selected. Only a single Disease term can be as-
sociated with an EID. If the clinical evidence associated
with the CIViC Variant is implicated in multiple dis-
eases, then multiple Evidence Items should be created. If
the disease cannot be identified in the Disease Ontology,
the “Could not find disease” box can be selected and a
new field will appear that permits free text entry. In this
case, it is recommended to submit a request to the Dis-
ease Ontology Term Tracker for addition of the missing
disease term (http://disease-ontology.org/faq/).
The Evidence Level describes the robustness of the
study supporting the Evidence Item. Five Evidence Levels
are currently available: Validated association (A), Clinical
evidence (B), Case study (C), Preclinical evidence (D),
and Inferential evidence (E) (Additional file 1: Figures S17
through S21). Validated EIDs (A) have a proven or clinical
consensus on the variant association in clinical practice.
Typically, these Evidence Items describe Phase III clinical
trials, regulatory approvals, or have associated companion
diagnostics. Clinical EIDs (B) are typically clinical trials or
other primary patient data supporting the clinical associ-
ation. These EIDs usually include more than 5 patients
supporting the claim made in the Evidence Statement.
Case studies (C) are individual case reports or small case
series. Preclinical evidence (D) is derived from in vivo or
in vitro experiments (e.g., mouse models or cell lines) that
support clinical claims. Finally, Inferential EIDs (E) indir-
ectly associate the variant to the provided clinical evidence.
These can involve hypotheses generated from previous ex-
periments but not yet supported by experimental results. It
is possible for an Evidence Source to yield multiple EIDs
with different Evidence Levels, for instance Level B and
Level C EIDs (See Additional file 1: Figure S22).
The Evidence Type refers to the type of clinical (or
biological) association described by the Evidence Item’s
clinical summary. Five Evidence Types are currently
supported: Predictive (i.e., Therapeutic), Diagnostic,
Prognostic, Predisposing, and Functional. Each Evidence
Type describes the clinical or biological effect a variant
has on the following: therapeutic response (Predictive),
determining a patient’s diagnosis or disease subtype
(Diagnostic), predicting disease progression or patient
survival (Prognostic), disease susceptibility (Predispos-
ing), or biological alterations relevant to a cancer pheno-
type (Functional) (Additional file 1: Figures S23
through S27). Selecting an Evidence Type has implica-
tions on available selections for Clinical Significance, as
outlined in Fig. 3.
The Evidence Direction indicates if the Evidence
Statement supports or refutes the clinical significance of
an event. The available options include: “Supports” or
“Does not support”. Nuanced examples for how to cor-
rectly use the Evidence Direction for Predictive Evidence
Types are shown in Additional file 1: Table S6 and Add-
itional file 1: Figure S28.
Clinical Significance describes how a CIViC Variant
is related to a specific clinical interpretation as described
in the Evidence Statement. The available options for Clin-
ical Significance depend on the Evidence Type selected for
the Evidence Statement. These options are shown in Fig. 3
with details in Additional file 1: Table S7. In brief, they de-
scribe the severity or type of treatment response (Predict-
ive), inclusivity or exclusivity of a cancer type or subtype
(Diagnostic), the type of outcome (Prognostic), or the type
of biological change (Functional). Note that Predisposing
Evidence Items may include ACMG-AMP evidence codes
[10] in the Evidence Statement; however, they do not dir-
ectly support an annotated Clinical Significance the way
other Evidence Types do, and Predisposing Clinical Sig-
nificance instead defaults to N/A. This is because most
variants will be considered of unknown predisposing sig-
nificance based on data derived from a single study. CIViC
Assertions based on aggregate data handle Predisposing
Clinical Significance and are described below.
The Evidence Rating is scored on a scale from 1 to 5
stars reflecting the Curator’s confidence in the quality of
the summarized evidence (Additional file 1: Figures S29
through S33). This rating depends on a number of factors,
including study size, study design, orthogonal validation,
and reproducibility. Although the overall publication/
study/abstract might be high quality, the Evidence Rating
may be low for an Evidence Item referring to a single con-
clusion in the study that is not well supported. The Evi-
dence Rating therefore does not rate the journal,
publication, or Evidence Source itself, but instead evalu-
ates in isolation the components of evidence extracted
from the Evidence Source. While this remains a somewhat
subjective measure, general best-practices for the Evidence
Rating are provided in Additional file 1: Table S8.
The Evidence Statement is a brief summary of the
clinical implications of the Variant in the context of a
specific Disease, Evidence Type and Clinical Significance
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as described in the cited literature source. An Evidence
Statement should synthesize the information from a
published study relevant to the clinical association of the
CIViC Variant. Evidence Statements should be as brief
as possible (typically 1 to 3 sentences), but include suffi-
cient experimental detail to interpret and evaluate the
evidence without repeating the original text or using
domain-specific acronyms or colloquialisms. Such details
include the type of study (e.g., phase, design), controls
used, outcomes measured, the number of individuals in-
volved and relevant statistical values (e.g., p-values, R2,
confidence intervals). Data constituting protected health
information (PHI) should not be entered in the Evidence
Statement field.
For Predictive evidence items, a Drug Names field will
become available. Multiple drugs can be added to a single
Evidence Item, requiring a Drug Interaction Type (Com-
bination, Sequential, or Substitutes) that describes the rela-
tionship of these drugs in the study. The Drugs and Drug
Interaction Types should be explicitly stated in the source
supporting the Evidence Item and not inferred by the Cur-
ator. Trade names should not be used for Drugs. When
available Drug Names are taken from the NCI Thesaurus
(https://ncit.nci.nih.gov See Additional file 1: Figure S34).
Older drug names/aliases should be referred to by their
newer name in the Drug field while mentioning the old and
new name in the Evidence Statement to minimize confu-
sion (see Additional file 1: Figure S20).
When additional phenotypes not captured by the Dis-
ease field alone are indicated, Associated Phenotypes
available in the Human Phenotype Ontology (HPO) data-
base [26] can be added to any Evidence Item. Associated
Phenotypes should provide additional information beyond
what is implied by the Disease field. Phenotypes should be
particularly considered for Predisposing Evidence Items
whereby the given Variant is associated with a non-binary
phenotype or syndrome for a particular genotype.
The last field in the Evidence Item submission form
permits free-form text for additional comments about
the Evidence Item. For example, Curators can call an
Editor’s attention to a particular comment using macro
notation (Additional file 1: Table S9). These comments
will appear first in the item’s comment thread and will
be visible to Editors during review.
Structure and curation of the Assertion knowledge model
Structure of the Assertion knowledge model
The CIViC Assertion summarizes the clinical relevance
of a CIViC Variant in a specific disease context using a
collection of Evidence Items (Fig. 4). Consistent with
Evidence Items, Assertions include a Gene, Variant,
Variant Origin, Disease, Assertion Type, Assertion
Direction, Clinical Significance, Drug (Predictive), Drug
Interaction Type (Predictive), and Associated
Phenotypes (optional). Fields unique to Assertions in-
clude annotation with clinical guidelines such as Associ-
ation for Molecular Pathology (AMP) Tier and Level
from the AMP-ASCO-CAP 2017 guidelines [11], ACMG
criteria from the ACMG-AMP 2015 guidelines [10], Na-
tional Comprehensive Cancer Network (NCCN) guide-
line/version, and FDA approvals/diagnostics. A short,
one sentence Summary and a longer Description of the
Assertion are also required for submission. If available,
existing Evidence Items should be associated with the
Assertion to support the Summary/Description. An As-
sertion can not be accepted without at least one ac-
cepted EID. The Assertion curation form can be found
in Additional file 1: Figure S35.
Curating within the assertion knowledge model
The Gene Name and Variant Name for an Assertion
have curation constraints. Assertions can only be created
for Genes and Variants associated with at least one Evi-
dence Item and are selected from an auto-populated list
using type-ahead search. Variant Names are restricted to
those associated with the selected Gene. The Variant
Origin follows the same guidelines as described for Evi-
dence Items (Additional file 1: Figure S36).
The Disease associated with the Assertion must
already exist within the CIViC database. Only one Dis-
ease is permitted for each Assertion. It is recommended
that the Disease be as specific as possible while still
holding true for all Evidence Items associated with the
Assertion (e.g., an Assertion for “non-small cell lung
cancer” can be supported by Evidence Items associated
with “lung adenocarcinoma” and “non-small cell lung
cancer” as well as general disease categories such as
“cancer”) (Additional file 1: Figure S37).
CIViC currently supports the following Assertion
Types: Predictive, Diagnostic, Prognostic, and Predispos-
ing. As with the Evidence Item submission form, selecting
an Assertion Type will alter available choices for Clinical
Significance, as outlined in Fig. 4. Options for Assertion
Direction include “Supports” and “Does not Support”.
Predictive, Prognostic or Diagnostic Assertions (Fig. 5a,
Additional file 1: Figures S38, S39, S40), utilize the somatic
variant interpretation guidelines, providing an AMP-
ASCO-CAP Tier (I-IV) and Level (A-D) [11]. Predisposing
Assertions (Fig. 5b, Additional file 1: Figure S41) utilize
the ACMG-AMP 2015 guideline classifications (Patho-
genic, Likely Pathogenic, Likely Benign, Benign and Vari-
ant of Unknown Significance), their predicate ACMG
evidence codes (i.e., PVS1, PP2, etc), and rules for combin-
ing criteria [10], as well as recommended updates [27–29].
Assertions are classified based on the combination of evi-
dence [EIDs and public sources (e.g., gnomAD, CADD)],
associated with the Assertion. The Assertion Description
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should specify the guidelines or classification system
used.
Optional descriptive fields for Assertions include As-
sociated Phenotypes and NCCN Guideline(s)/Ver-
sion(s) (Additional file 1: Figure S35). If the Variant-
Disease association described by the Assertion has a
cleared/approved FDA companion diagnostic or a drug
with FDA Regulatory Approval, then the appropriate
box should be checked.
Each Assertion requires a one-sentence Summary and
a longer, more complete Description of the Assertion.
The Description is designed to capture special
considerations or additional data (e.g., specific treatment
regimens, source of ACMG codes) used by the Curator
to assemble the Assertion. Important specific details
from practice guidelines (e.g. NCCN) should be included
in the Summary, including disease stage, and in the case
of predictive Assertions, treatment line (e.g., first line,
second line, salvage) which practice guidelines
recommend.
The Supporting Evidence grid allows users to associ-
ate Evidence Items with Assertions. This collection of
Evidence Items should cover the important clinically
relevant findings for the CIViC Variant in the context of
Fig. 4 Diagram of knowledge model for CIViC Assertions. Assertions summarize a collection of Evidence Items to make a definitive clinical
statement about the Variant in a specific Disease context which incorporates all known data within the knowledgebase. Assertions features
(green box) build on the Evidence Item knowledge model to bring together clinical guidelines, public resources, and regulatory approvals
relevant to a final variant interpretation. Assertions can be associated with any number of Evidence Items. Like Evidence Items, Assertion Type,
Direction, and Clinical Significance can be used to create a specific meaning for the Assertion
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a specific cancer. For Predictive Assertions, the collec-
tion of Evidence Items should also consider the Drug(s)
and their Drug Interaction Type. Assertions do not re-
quire Evidence Items for development; however,
complete (revised and accepted) Evidence Items must
be added to the Assertion before it can be accepted
by CIViC Editors (Additional file 1: Figure S42). Min-
imal Evidence Item requirements for AMP-ASCO-
CAP Tier and Level are shown in Additional file 1:
Table S10.
Conclusions
While an earlier publication has introduced the CIViC
database [12], no publication has yet offered a compre-
hensive documentation and SOP of the complex cur-
ation practice developed over 4 years of work by the
CIViC community worldwide. CIViC has been adopted
by a growing number of external organizations. Various
gene/disease curation task teams that are part of the
ClinGen Somatic Cancer Working Group have now
adopted CIViC as their preferred tool for curation of
Fig. 5 CIViC Assertion development by Assertion Type. CIViC Assertions summarize a collection of Evidence Items which reflect the state of
literature for the given variant and disease. a For Assertion Types typically associated with somatic variants (Predictive, Prognostic, or Diagnostic),
AMP-ASCO-CAP 2017 guidelines are followed to associate the Assertion with an AMP Tier and Level, which involves consideration of practice
guidelines as well as regulatory approvals associated with specific drugs, as well as consideration of available clinical evidence in the absence of
explicit regulatory or practice guidelines. b CIViC Predisposing Assertions utilize ACMG-AMP 2015 guidelines to evaluate the 5-tier classification for
a variant in a given disease context, which is supported by a collection of CIViC Evidence Items, along with other data. ACMG evidence codes for
an Assertion are supplied by a collection of supporting CIViC Evidence Items (e.g., PP1 from co-segregation data available in a specific
publication), and additionally are derived from Variant data (e.g., PM2 from population databases such as gnomAD). ACMG evidence codes are
then combined at the Assertion level to generate a disease-specific classification for the Assertion
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somatic variants in cancer [30]. Data Clients for CIViC
now include WikiData, cBioPortal, GeneCards, UCSC
Genome Browser, GoldenHelix, MyVariantInfo and
many others (A complete list is found here: https://civic.
readthedocs.io/en/latest/about/data-clients.html). Cit-
ation of CIViC has also been used as supporting evi-
dence in ClinVar submissions (See ClinVar variant
523644). Submission of CIViC Assertions to ClinVar
also requires documented curation protocols for variant
tiering to obtain 1-star status. Finally, efforts to obtain
FDA recognition for the CIViC database and ClinGen
Somatic curation process are underway and would bene-
fit from documented curation procedures for CIViC.
Therefore, the need for a clear and peer reviewed CIViC
SOP is apparent. We hope that this work may build on
published SOPs for evaluation of evidence and curation
in this space [31, 32] and also function as a template for
other data curation efforts as they develop knowledge-
bases and methods for structured evaluation of evidence,
similarly integrating them into the clinical cancer com-
munity and regulatory bodies.
Implementation of this SOP will promote standardization
of data across CIViC, which is intended as a platform for the
generation and dissemination of a large volume of structured
data. Utility of large data sets is highly dependent on
standardization of the manner in which data is encoded into
the format [33, 34]. The free text section of an Evidence Item
(EID) - the Evidence Statement - is clearly an area where
guidelines for writing and structuring are essential. For in-
stance, when followed, the Predisposing Evidence Statement
format (Additional file 1: Figure S26) allows for rapid ascer-
tainment and review of derived ACMG-AMP 2015 codes
[10] for the disease and Variant from the particular Evidence
Source. Although structured data fields are more con-
strained, they also require guidelines for standardization of
curated data. For example, the Reduced Sensitivity annota-
tion has been restricted to comparison of CIViC Variants
under the same treatment scenario (Additional file 1: Table
S6), whereas without explicit curation guidelines, this annota-
tion might erroneously be used in scenarios comparing
different drug efficacy against the same Variant, causing an-
notations which inconsistently classify clinical data.
Multiple efforts exist to aggregate, formalize and struc-
ture cancer variant data, or provide classification and clin-
ical tiering of somatic or germline variation. Publication of
SOPs can help clarify interrelation between these different
efforts. For instance, considering the guidance described
here for Predictive (Therapeutic) annotations in CIViC
(Additional file 1: Table S6 and Figure S28), mappings of
these annotations between CIViC and other knowledge-
bases can be made, such as to Sensitivity and Resistance
categories of OncoKB [35] (Additional file 1: Figure S43).
Peer reviewed SOPs can facilitate clear comparison be-
tween curation efforts and tiering guidelines, and in this
particular instance, our SOP offers a standardized struc-
ture for CIViC data from initial curation through to the
endpoint where collections of CIViC evidence are inte-
grated into Assertions built on ACMG-AMP or AMP-
ASCO-CAP guidelines, and can be developed to accom-
modate other guidelines emerging in the field.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13073-019-0687-x.
Additional file 1. Supplementary Materials, contains supplemental
figures and tables outlining curation SOP guidelines illustrated by
workflow figures, tables, and screenshots from the CIViC interface.
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